ViroMed receives US FDA Approval of Phase II trial for VM202
Published: 2009-07-24 06:58:00
Updated: 2009-07-24 06:58:00
ViroMed Co., a local pharmaceutical firm, announced on July 21 that VM202-PAD, the company’s proprietary DNA medicine for the treatment of peripheral artery disease (PAD), has received approval from the US Food and Drug Administration for a Phase II clinical trial.
The trial will be performed...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
